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Abstract: A nanohybrid was prepared with an inorganic clay material, montmorillonite (MMT), 
for taste masking of sildenafil (SDN). To further improve the taste-masking efficiency and 
enhance the drug-release rate, we coated the nanohybrid of SDN–MMT with a basic polymer, 
polyvinylacetal diethylaminoacetate (AEA). Powder X-ray diffraction and Fourier transform 
infrared experiments showed that SDN was successfully intercalated into the interlayer space 
of MMT. The AEA-coated SDN–MMT nanohybrid showed drug release was much suppressed 
at neutral pH (release rate, 4.70 ± 0.53%), suggesting a potential for drug taste masking at the 
buccal cavity. We also performed in vitro drug release experiments in a simulated gastric fluid 
(pH = 1.2) and compared the drug-release profiles of AEA-coated SDN–MMT and Viagra®, 
an approved dosage form of SDN. As a result, about 90% of SDN was released from the AEA-
coated SDN–MMT during the first 2 hours while almost 100% of drug was released from 
Viagra®. However, an in vivo experiment showed that the AEA-coated SDN–MMT exhibited 
higher drug exposure than Viagra®. For the AEA-coated SDN–MMT, the area under the plasma 
  concentration–time curve from 0 hours to infinity (AUC0-∞) and maximum concentration (Cmax) 
were 78.8 ± 2.32 µg ⋅ hour/mL and 12.4 ± 0.673 µg/mL, respectively, both of which were larger 
than those obtained with Viagra® (AUC0-∞ = 69.2 ± 3.19 µg ⋅ hour/mL; Cmax = 10.5 ± 0.641 µg/mL). 
Therefore, we concluded that the MMT-based nanohybrid is a promising delivery system for 
taste masking of SDN with possibly improved drug exposure.
Keywords: montmorillonite, nanohybrids, polyvinylacetal diethylaminoacetate, sildenafil 
citrate, taste masking
Introduction
There have been many attempts to explore new nanohybrids with the desired 
physicochemical and biological properties, such as inorganic–organic nanohybrids with 
two-dimensional limited high-temperature superconductivity,1 bio–inorganic nanohy-
brids with enhanced gene delivery characteristics,2–4 intravenous injectable drug-delivery 
systems,5 and various therapeutic agent-delivery systems with high efficiency.6–13 Among 
various inorganic nanohybrids, the most widely studied for pharmaceutical applica-
tion were smectite clays as formulation additives. For taste masking in this study, we 
employed a smectite clay material that can swell and encase a drug.
The unpleasant taste of drugs has been one of the major limitations for designing 
oral drug formulations since swallowing a tablet may be the only option for the 
drug to bypass taste perception in the buccal cavity. However, such methods for drug 
administration still require the patients’ cooperation to a large extent and may be 
inconvenient, especially for drugs needing punctual or sudden dosing schedules.
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For this reason, sildenafil (SDN) citrate may be a drug 
that needs a delivery strategy other than a tablet formulation 
for swallowing. SDN, an inhibitor of cyclic guanosine mono-
phosphate-specific phosphodiesterase type 5, has been used 
for treatment of erectile dysfunction and is already approved 
as a tablet dosage form for oral delivery (Viagra®; Pfizer, 
New York, NY). The nature of this specific drug therapy 
implies that the dosing moments are mostly unexpected or 
sudden, and for patient convenience, an easier administration 
method other than swallowing is needed. Redesigns of the 
formulations, such as chewable or dissolvable tablets,14–17 or 
rapidly dissolving film,18–20 would be desirable, but may not 
be practical for SDN delivery due to its unpleasant taste.21
Therefore, taste masking of SDN may be needed for orally 
disintegrating formulations to ensure patient compliance and 
improve acceptability of medication. Previously, numerous 
attempts have been made in the field of taste masking, where 
most approaches were based on encapsulation of drugs with 
polymeric materials, such as cellulose, Eudragit® (Evonik 
Industries AG, Essen, Germany), or polyethylene glycol, 
among others.22–24 The purpose of encapsulation was primarily 
focused on suppressed release of drugs in biological fluids 
with no (or almost no) free drug molecules available at the 
buccal cavity. However, for those conventional approaches, the 
diffusion barrier formed by polymeric materials would still be 
in effect while the formulations pass through the gastrointestinal 
tract, where the drug release would be undesirably suppressed. 
This is not beneficial, especially for SDN delivery, since the 
drug requires rapid systemic absorption for its own therapeutic 
purpose. To resolve this problem, the delivery profile of SDN 
should be specifically tailored: the drug release should be 
highly suppressed at the buccal cavity and then released rapidly 
in the gastrointestinal fluid.
Some previous studies utilized polymers with pH-
dependent solubility as an encapsulant, where the barrier 
polymer dissolves only at low pH, with controlled release 
of the drug in the gastric cavity, not in the buccal cavity.25–27 
Although this selective delivery profile may benefit from 
both taste masking and rapid drug release to some extent, 
the formulations may not yet be optimized for the follow-
ing reasons. The drug molecules may be distributed on the 
surface of the polymeric encapsulant slightly, which may 
still cause a bitter taste. The delayed dissolution of polymers 
may still inhibit rapid onset of drug release and the systemic 
absorption of drugs may be retarded altogether.
In this study, we prepared a bentonite-based nanohybrid 
coated with an acid-soluble polymer to better achieve both 
taste masking and rapid delivery of SDN. Bentonite, mainly 
composed of montmorillonite (MMT), consists of tetrahedral 
sheets of SiO4 units and octahedral sheets of Al3+ ions.28,29 The 
isomorphous substitution of Al3+ with Mg2+ can generate a 
negative surface charge on bentonite. To balance the excess 
negative charge, the interlayer cations are stabilized within 
the layers and as a result, bentonite possesses cation-  exchange 
capacity (CEC). Therefore, the cationic drug SDN could be 
encased in the layered space of MMT with strong ionic bond-
ing, producing an SDN–MMT nanohybrid with taste-masking 
functionality. The nanohybrid was also coated with an acid-
soluble polymer, polyvinylacetal diethylaminoacetate (AEA), 
to further prevent drug release in the buccal cavity and aid 
rapid release in the stomach. For the latter, we reported that 
the presence of a large molecule possessing the same polarity 
as the intercalated compound facilitated the diffusion of the 
intercalated compound by enlarging the entrance of layered 
structures of MMT.30–32 The carrier material, MMT clay, 
employed in this work is approved by the US Food and Drug 
Administration (FDA) as a diluting agent for oral delivery 
and is widely used in medicine and pharmacology.33,34 The 
polymer used for coating, AEA, is also accepted as a food 
additive by the FDA.35
In this study, we developed an SDN–MMT nanohybrid 
with taste-masking functionality and compared its drug-release 
profile with that of Viagra®, an SDN medication available on 
the market. We aimed to prove that our SDN–MMT nanohybrid 
formulation was advantageous in its therapeutic efficacy as well 
as in administration strategy. Our SDN–MMT nanohybrid was 
characterized with powder X-ray diffraction (PXRD), Fourier 
transform infrared (FT-IR) spectra, and thermogravimetry 
(TG) analysis to examine the properties of SDN intercalated 
in MMT. The release profiles of SDN with both noncoated and 
AEA-coated SDN–MMT nanohybrids were also examined in 
simulated biological fluids, using high-performance liquid 
chromatography (HPLC). To assess the drug bioavailability, 
the SDN–MMT formulations were compared with Viagra® 
through both in vitro and in vivo experiments.
Material and methods
Materials
Montmorillonite (MMT, Kunipia-F; CEC = 110 mequiv/100 g) 
and polyvinylacetal diethylaminoacetate (AEA) were obtained 
from Kunimine Industries Co, Ltd (Tokyo, Japan) and 
  Sankyo (Tokyo, Japan), respectively and used without further 
purification. Sildenafil (SDN) was a kind gift from Daewoong 
(Seoul, Korea). Acetonitrile, methanol, and glacial acetic acid 
of high performance liquid chromatography (HPLC) grade 
were purchased from JT Baker (Cleveland, OH).
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Preparation of SDN–MMT  
and AEA-coated SDN–MMT
The SDN–MMT nanohybrid was prepared by ion exchange 
reaction. Briefly, 20 g MMT was dispersed in 2 L deionized 
water for 3 hours at room temperature to give a 1.0 wt% 
MMT suspension. To prepare an SDN solution, 14.7 g SDN, 
which is equivalent to the CEC of 20 g MMT, was first 
dissolved in 1200 mL of a 1% phosphoric acid solution, and 
800 mL ethanol was added afterwards. The resulting solution 
was then mixed with the MMT suspension and stirred for 
4 hours at room temperature to facilitate an ion exchange 
reaction. The solid product, SDN–MMT, was then filtered and 
washed twice with 50% ethanol solution and pure ethanol, 
respectively, to remove the residual drug. The resulting 
SDN–MMT slurry (200 g) was dispersed again in a mixture 
of methylene chloride (MC) and ethanol (MC: ethanol, 
200 mL: 400 mL, v/v) and spray-dried with an SD-1000 spray 
dryer (Eyela, Tokyo, Japan) under the following conditions: 
inlet temperature, 80°C; blower speed, 0.30 m3/minute, and 
atomizing pressure, 125 ± 5 kPa.
To prepare the AEA-coated SDN–MMT, the SDN–
MMT slurry (200 g) was dispersed in a mixture of MC and 
ethanol (MC: ethanol, 200 mL: 400 mL, v/v), where 10 g 
AEA was dissolved. The resulting suspension was then 
spray-dried with a spray dryer under the same conditions 
stated above.
Characterization of nanohybrids
The PXRD patterns of both SDN–MMT and AEA-coated 
SDN–MMT were collected using a Rigaku D/MAX-2200 
Ultima diffractometer (Rigaku International Corporation, 
Tokyo, Japan) equipped with Ni-filtered Cu-Kα radiation 
(λ = 1.5418 Å). The patterns were recorded at 40 kV and 
30 mA. TG analysis was performed at a heating rate of 
5°C/minute from room temperature to 1000°C under ambient 
atmosphere (SDT Q600; TA Instruments, New Castle, DE). 
FT-IR spectra (Figure S1) were recorded with a JASCO FT/
IR-6100 spectrophotometer (JASCO, Easton, MA) by the 
standard KBr disk method. The particle size (Figure S2) of 
SDN–MMT and AEA-coated SDN–MMT were obtained 
with dynamic light-scattering method (ZetaSizer; Nano 
ZetaSizer, Malvern Instruments, Malvern, UK).
Determination of SDN content
To determine the amount of SDN, SDN needs to be 
  completely extracted from the SDN–MMT nanohybrids. 
Thus, the solution was first prepared with an aqueous solution 
buffered at pH 4.5 (KH2PO4), acetonitrile and phosphoric acid 
(400:600:1, v/v/v). Then, each of the samples containing the 
equivalent amount of 6 mg SDN was dispersed in 100 mL 
of the resulting solution and sonicated for 40 minutes. The 
suspension was filtered by a polypropylene membrane with 
a pore size of 0.45 µm (Pall, Port Washington, NY), which 
was then measured with HPLC (1100 Series Instrument; 
Agilent Technologies, Santa Clara, CA) using a column, 
Zorbax Eclipse XDB-C18 (4.6 mm × 250 mm, 5 µm; Agilent 
Technologies). The mobile phase was prepared with an aque-
ous solution buffered at pH 4.5 (KH2PO4) and acetonitrile 
(40:60, v/v). The samples were analyzed under the following 
conditions: flow rate, 1 mL/minute; injection volume, 10 µL; 
column temperature, 35°C; and UV wavelength, 230 nm.
In vitro drug release experiment
The in vitro drug release tests were conducted with intact 
SDN, SDN–MMT, AEA-coated SDN–MMT, and Viagra®, 
following the paddle-stirring method using a DST-810 
dissolution tester (LabFine, Seoul, Korea).36 The bath 
temperature was maintained at 37°C ± 0.5°C and the 
impeller was set at 50 rpm. Each sample containing the 
equivalent amount of 50 mg SDN was dissolved in 900 mL 
of the release media, the aliquot of which was sampled 
at scheduled intervals. The aliquot was then filtered with 
a polypropylene membrane with a pore size of 0.45 µm 
(Pall), which was measured with the HPLC as described 
above in ‘Determination of SDN content’. In this work, 
two distinct release media were employed to simulate the 
buccal and gastric cavities, respectively. To simulate the 
buccal condition and evaluate the taste-masking ability of 
the nanohybrids, the release test was performed at neutral 
pH for 2 minutes, following the International Pharmaceutical 
Federation/American Association of Pharmaceutical Sciences 
guidelines.37 To simulate the gastric conditions, the release 
test was performed at pH 1.2 for 2 hours.
In vivo experiment
Preparation of standard solutions and animals
The stock solution of SDN was prepared at a concentration 
of 50 µg/mL in methanol and was further diluted to 
0.1∼4.0 µg/mL for plasma calibration standards. The solutions 
of six different concentrations, covering the expected ranges 
of 2∼200 ng/mL, were prepared. Six male beagle dogs, 
8.5 months old and weighing 12∼15 kg, were purchased from 
Central Lab Animal (Seoul, Korea). The animals were fasted 
overnight with free access to water. Viagra® or AEA-coated 
SDN–MMT was orally administered to each dog at a dose of 
20 mg/kg (n = 3). The SDN dose was selected on the basis 
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of the pharmacological and pharmacokinetic data published 
previously.38 The Viagra® tablets were ground into powder, 
which was weighed to match the dose of SDN. OASIS HLB 
96-well plates (10 mg; Waters Corporation, Milford, MA) 
were utilized for solid-phase extraction (SPE) of the analytes 
in plasma samples. In all instances, animals were humanely 
handled in accordance with Institutional Animal Care and 
Use Committee guidelines.
Analytical method development
Blood sampling and HPLC-ESI-MS/MS analyses
Approximately 5 mL of blood was collected from a right 
front leg vein at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, and 24 hours 
after oral dosing. The cannula was filled with heparinized 
saline (500 IU mL−1) to prevent blood clotting, and then the 
blood samples were taken after centrifugation and stored 
at −70°C until analysis.
An OASIS HLB 96-well SPE plate (Waters Corporation) 
was used for the extraction of the analyte from the plasma 
samples. Aliquots of 200 µL of 6% perchloric acid were 
added into the 300 µL of blank or plasma sample in a 
1.5 mL microtube to precipitate the protein. The mixture 
was vortexed for 10 seconds, then centrifuged at 15,000 × g 
for 10 minutes. The supernatant was immediately loaded 
onto each well of OASIS HLB plate, previously conditioned 
with 600 µL of methanol followed by 600 µL of water. The 
whole wells were washed with 600 µL of water and then air-
dried for about 30 seconds. The attached analyte was eluted 
twice with 200 µL of 5% methanolic ammonium hydroxide 
(conc NH4OH/methanol, 5:95, v/v), then evaporated to 
dryness at room temperature by vacuum centrifugation. The 
residues were reconstituted to 200 µL with methanol, and 
a twentieth (10 µL) of the solution was subjected to HPLC-
electrospray ionization mass spectrometry/mass spectrometry 
(ESI-MS/MS) analysis.
All HPLC-ESI-MS/MS experiments were carried out using 
a Waters/Micromass Quattro micro/MS interface consisting 
of a Waters 2695 separation module connected directly to a 
Micromass Quattro micro/MS (Waters Corporation). Separa-
tion was performed on a 30 mm × 2.1 mm Xterra MS C18 
(3.5 µm; Waters Corporation) reversed-phase column. The 
analytes were eluted at a flow rate of 180 µL/minute with an 
isocratic system of 24% (v/v) aqueous acetonitrile with 0.1% 
acetic acid for 7 minutes. The column effluent was directed 
to the ESI-MS, which was operated in the positive ion mode 
without splitting. The instrument was tuned by the direct 
infusion of a stock solution of SDN (2 µg/mL in methanol) in 
the ion source at 40 µL/minute. The optimization parameters 
of the ESI-MS/MS system were based on the maximum 
generation, first of the protonated molecular (parent) ions, 
and then of the corresponding fragment (product) ions. The 
following tuning parameters were retained for the optimum 
ESI-MS/MS detection of SDN: the capillary voltage and 
cone voltage were 2 kV and 35 V , respectively; the source 
and desolvation temperatures were 130°C and 250°C, 
respectively; the desolvation gas and cone gas flow rates 
were 500 L/hour and 50 L/hour, respectively. The collision 
energy in the MS/MS mode, concurring with full argon-
induced fragmentation of the parent molecules, was found 
to be 0.27 V. The quantification of SDN was conducted 
using MS/MS in multiple reaction monitoring (MRM) mode. 
This was done by choosing the two mass ions set to detect 
a transition of the parent ion to the product ion specific to 
SDN (474.7 . 99.9). The molecular structures and major 
fragmentation pattern for SDN are shown in Figure 1.
HPLC-ESI-MS/MS analytical method validation  
for SDN in in vivo samples
Linearity of calibration was assessed by analyzing six 
standards ranging from 2∼200 ng/mL in plasma. The 
calibration curve was based on drug peak area and was 
analyzed by weighted linear regression using the Sigmaplot 
program (v. 8.0; SPSS Inc, Chicago, IL). The correlation 
coefficient was calculated. The limit of quantification 
(LOQ) was defined as the drug concentration producing at 
least ten times the response compared to the blank response 
(S/N . 10). Quality control (QC) samples were prepared at 
low (5 ng/mL), medium (50 ng/mL), and high concentration 
(150 ng/mL) in the same way as the plasma calibration 
samples. Intra- and Interday precision and accuracy were 
assessed by analyzing the above-mentioned QC samples 
with five replicates on three different days, and they were 
presented as relative standard deviations (RSD). Recoveries 
of the analytes spiked into plasma samples at three different 
concentrations (2, 20, and 100 ng/mL) were calculated by 
comparing the peak area of the extracted sample to that of 
the unextracted standard solution prepared with the same 
solvent, and each experiment at the same concentrations was 
done in triplicate. Stability of SDN was conducted using QC 
samples after three freeze–thaw cycles, at room temperature, 
and after post-preparation procedures.
Pharmacokinetic study
Pharmacokinetic parameters were determined from the 
plasma SDN concentration–time data by noncompartmental 
analysis using WinNonlin Professional software (v. 2.0; 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1638
Lee et alInternational Journal of Nanomedicine 2012:7
Pharsight Co, Mountain View, CA). The pharmacokinetic 
parameters estimated from the data were area under the 
plasma concentration–time curve from 0 hours to infinity 
(AUC0-∞), elimination half-life (t1/2), apparent volume of 
distribution (Vd/F), and total clearance (Cl/F). The maximum 
plasma concentration (Cmax) and the time required to reach 
Cmax (Tmax) were determined from the individual plasma 
concentration–time curve by visual inspection.
Statistical analysis
All the results were presented as means ± standard deviations. 
An unpaired Student’s t-test was used to determine significant 
differences between the SDN and AEA-coated nanohybrid 
data. Differences were considered to be significant when 
P , 0.05.
Stability test
The shelf-life of SDN for SDN–MMT and AEA-coated 
SDN–MMT nanohybrids were examined through an 
accelerated stability test.39 Each of the samples was put in 
a glass vial and sealed, which was then placed in a constant 
temperature and humidity chamber (LH-1000; New Power 
Engineering, Seoul, Korea) for 6 months. The temperature 
and humidity were maintained at 40°C and 75%, respectively. 
The amount of nondegraded SDN was measured with HPLC 
as described above in “Determination of SDN content”. 
For each of the samples, the fraction of nondegraded SDN 
was calculated by percentage based on the SDN content 
measured initially before the stability test.
Results and discussion
Powder X-ray diffraction analysis
Figure 2 shows the PXRD patterns of intact SDN, pristine 
MMT, SDN–MMT, and AEA-coated SDN–MMT. For 
pristine MMT, the characteristic peak of (001) was clearly 
seen at 6.9° (Figure 2B), which was shifted to 3.8° for both 
SDN–MMT and AEA-coated SDN–MMT nanohybrids 
(Figure 2C and D). This could be ascribed to the expanded 
basal spacing of MMT from 12.5 Å to 22.8 Å after 
intercalation of SDN. There was no difference in the PXRD 
patterns between the SDN–MMT and the AEA-coated 
SDN–MMT nanohybrids, implying that SDN still resided 
in the interlayer space of the MMT after the AEA coating. 
The peaks of intact SDN (namely, crystalline SDN) were not 
observed with SDN–MMT and AEA-coated SDN–MMT 
nanohybrids, indicating that SDN molecules were distributed 
in the MMT interlayer space with a molecular level as 
reported previously in other nanohybrid systems.32,40
Subtracting the layer thickness of MMT (9.3 Å) from 
the basal spacing of SDN–MMT, the gallery height was 
estimated to be 13.5 Å. Considering that the longitudinal 
and lateral molecular dimension of SDN are 5 Å and 16 Å, 
respectively, it became very likely that the SDN molecules 
should be stabilized in a double-layer arrangement. To 
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Figure 1 Chemical structure of sildenafil and its electrospray ionization mass spectrometry/mass spectrometry fragmentations.
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explain this, the steric limitations between the intercalated 
SDN and charged sites of MMT layers were examined. 
The steric limitations are generally expressed by the 
equivalent area (Ae) of clay lattices and the area demand 
(Ac) of intercalated molecules. The Ae can be estimated 
from the equation Ae = ab/2ξ, where a and b are lattice 
parameters and ξ is the layer charge. The Ae of MMT 
was estimated to be 28.85 Å2, calculated using a negative 
charge density, 0.27e-/46.5 Å2.41 The area demand (Ac) of 
SDN was about 136 Å2, calculated from the molecular 
model in Figure 3B. Thus, since Ac is larger than 2Ae, SDN 
molecules should have a tilted bilayer arrangement to avoid 
steric hindrance.31,42 The protonation sites of SDN should 
be only at N22 as shown in Figure 1 since protonation in 
combined rings of pyrimidine and pyrazole is unlikely 
due to resonance and steric effects.43 As a result, the SDN 
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Figure 2 Powder X-ray diffraction patterns of (A) sildenafil citrate, (B) montmorillonite (MMT), (C) sildenafil–montmorillonite (SDN–MMT), and (D) polyvinylacetal 
diethylaminoacetate (AEA)-coated SDN–MMT.
Note: *Quartz.
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Figure 3 Schematic descriptions for (A) sildenafil–montmorillonite (SDN–MMT) and (B) sildenafil (SDN) molecules drawn by ChemBio3D Ultra 12.0 program (Cambridge 
Soft, Cambridge, MA).
Notes: carbon, gray; nitrogen, blue; oxygen, red; sulfur, yellow; hydrogen, white.
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molecules should be arranged in the interlayer space of 
MMT as depicted in Figure 3A.
Thermogravimetric analysis
Figure 4 depicts the TG curves of pristine MMT, intact SDN, 
and SDN–MMT. For pristine MMT, the first weight loss up 
to 100°C was due to the evaporation of water adsorbed on 
the MMT surface (Figure 4C). The weight loss observed at 
600°C was attributed to dehydroxylation and phase transition 
of MMT. The intact SDN exhibited three consecutive weight 
losses (Figure 4A). The first weight loss at 188°C was due 
to the decomposition of citrate and the second weight loss 
at 270°C was ascribed to the decomposition of the SDN 
molecule itself. The intact SDN was completely decomposed 
above 326°C, corresponding to the last weight loss. For 
SDN–MMT (Figure 4B), the weight loss due to dehydration 
was seen up to 200°C. The following weight loss from 250°C 
to 750°C was due to the decomposition of intercalated SDN. 
Interestingly, the decomposition temperature of SDN in 
the nanohybrid (250°C) was lower than that of intact SDN 
(270°C).This result could be due to the molecular distribution 
of SDN upon intercalation, which would possibly lead to the 
enhancement of SDN solubility.31,44
SDN content in nanohybrids
The SDN content of the SDN–MMT and AEA-coated 
SDN–MMT nanohybrids was 30.61% ± 0.55% and 
16.59% ± 0.44%, respectively. The decrease in SDN content 
with AEA-coated SDN–MMT was due to incorporation of 
the AEA polymer through the coating process employed in 
this work (MMT:AEA = 1:1 w/w).
In vitro drug release test
We prepared our nanohybrid system to mask the taste of SDN. 
To assess this quality, we conducted an in vitro drug-release 
experiment in deionized water for 2 minutes, mimicking 
the condition in the buccal cavity.37 As shown in Table 1, 
for intact SDN, more than 73% of the drug was dissolved 
rapidly into the release media as expected. Almost half of 
SDN was released from Viagra® during the first 2 minutes 
since the tablet is designed to rapidly release the drug in the 
biological fluid. In contrast, the nanohybrids (ie, SDN–MMT 
and AEA-coated SDN–MMT) exhibited greatly suppressed 
release under the test condition employed in this work. The 
SDN release from the nanohybrids was more than tenfold 
less than that from intact SDN and Viagra®: the SDN–MMT 
exhibited no release, and for AEA-coated SDN–MMT, only 
a slight portion of the drug (,5%) was released during the 
first 2 minutes. The strong ionic interaction between the SDN 
molecules and the MMT interlayers appeared to hinder free-
ing the drug molecules, resulting in very low drug release. 
A slight drug release (,5%) from AEA-coated SDN–MMT 
could be due to slight dissolution and ionization of the AEA 
even in the neutral media to deintercalate the drug in the 
MMT to some extent.
In addition to taste masking, the SDN needs to be released 
rapidly in the gastric cavity for satisfactory therapeutic 
efficacy. Thus, we examined the drug-release profiles of 
SDN–MMT and AEA-coated SDN–MMT nanohybrids 
in a simulated gastric condition and compared them with 
those of intact SDN and Viagra® (Figure 5; Table S4). The 
drug release from intact SDN and Viagra® was very rapid as 
expected. More than 90% of SDN was released in 10 minutes 
and 99% during the first 2 hours, which could be attributed 
to high solubility of SDN in acidic fluid.45 However, the drug 
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Figure  4  Thermogravimetric  curves  of  (A)  sildenafil  citrate,  (B)  sildenafil–
montmorillonite (SDN–MMT), and (C) montmorillonite (MMT).
Table 1 In vitro drug dissolution profiles under a simulated buccal 
condition
Samples % drug releasea
1 minute 2 minutes
Viagra® 17.17 ± 4.2 48.78 ± 5.49
Sildenafil citrate 53.31 ± 7.47 73.66 ± 4.61
Noncoated nanohybrid 0.00 0.00
AEA-coated nanohybrid   0.66 ± 0.64   4.70 ± 0.53
Notes: aValues are mean ± SD; n = 3.
Abbreviations: AEA, polyvinylacetal diethylaminoacetate; SD, standard deviation.
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was hardly released from SDN–MMT (,3%) again due to 
the strong ionic interaction between the intercalated SDN 
and MMT. In spite of its excellent taste-masking properties 
(Table 1; Table S3), the SDN–MMT by itself may not be 
useful for effective delivery of SDN. On the other hand, 
drug release increased dramatically with the AEA-coated 
SDN–MMT nanohybrid. About 75% of SDN was released in 
10 minutes and up to 90% during the first 2 hours, which was 
only 10% less than Viagra®. The cationic macromolecule, 
AEA, when dissolved and ionized selectively at low pH, 
could replace the intercalated drug molecules effectively 
and enlarge the interlayer spacing to facilitate drug diffusion 
out towards the release media.31 This result is meaningful 
in a sense that AEA-coated SDN–MMT nanohybrids could 
provide both taste masking and effective in vitro release of 
SDN relatively similar to proven medications like Viagra®.
SDN analytical method validation
Under the HPLC-ESI-MS/MS conditions described in the 
experimental section, no interfering peak was detected 
in the plasma samples. MRM in a positive mode was 
used to quantify SDN (see Supplementary information). 
Figure S3 shows the typical product ion spectra of SDN, and 
the typical chromatograms of SDN detected with the MRM 
mode of HPLC-ESI-MS/MS are demonstrated in Figure S4. 
The calibration curve for SDN was generated by linear regres-
sion of peak area ratios against the injected amount of the 
analyte. The curves show good linearity over the calibration 
ranges in plasma (R2 = 0.9999). The LOQ, defined as a signal-
to-noise ratio of 10, was estimated at 1.2 ng/mL.
The intra- and interday precision and accuracy using the 
QC samples are shown in Table S1. The precisions (RSDs) 
are all less than 5%, and accuracy ranged from 91.7% to 
96.2% for intraday and 91.0% to 93.6% for interday, respec-
tively. This indicates the method is accurate and precise 
enough to apply in pharmacokinetic study.
The mean recoveries of SDN spikes in plasma at three 
different concentrations ranged from 91.4% to 93.6%, and 
the percentage of RSDs were all less than 7% (n = 3) (see 
Table S2 for supplementary information), demonstrating 
that the employed OASIS HLB method for SPE coupled 
with HPLC-ESI-MS/MS analysis seems to be suitable for 
detection of SDN in plasma samples. The stabilities of 
SDN spikes in plasma were studied under different storage 
conditions including three cycles of freeze-thawing, room 
temperature for 5 hours, and post-preparation for overnight. 
The deviation of the mean quantification data was within 
5% in all stability tests for QC samples, and there seems no 
significant effect (P , 0.5) on the quantification of SDN in 
the plasma samples.
Pharmacokinetics of SDN after oral 
administration of Viagra® and AEA-coated 
SDN–MMT to dogs
Figure 6 shows the mean plasma concentration–time curve 
of SDN after oral administration of Viagra® and AEA-coated 
100
80
60
R
e
l
e
a
s
e
d
 
f
r
a
c
t
i
o
n
 
(
%
)
40
20
0
01 02 04 0
Time (minutes)
60 90 120
A
B
C
D
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Note: The release experiments were performed at pH = 1.2.
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SDN–MMT to the beagle dogs. The relevant pharmacokinetic 
parameters are presented in Table 2. The AUC0-∞ and Cmax 
of SDN significantly increased in AEA-coated SDN–MMT 
nanohybrid compared with Viagra® (P , 0.05). Such a dif-
ference in drug exposure could be explained by individual 
pharmacokinetics variability, but the AUC0-∞ and Cmax values 
were still statistically meaningful between two groups, even 
though the number of the animals studied was small (n = 3). 
The increased drug exposure observed in AEA-coated SDN–
MMT seems to be most likely due to the decreased oral 
clearance of SDN (4.34 L/hour in Viagra® vs 3.81 L/hour 
in AEA-coated SDN–MMT; P , 0.05). According to the 
in vitro drug-release profiles (Figure 5), after the initial burst 
release (∼80%), 10% of drug was released slowly for the 
remaining 110 minutes. After 2 hours, the remaining 10% 
of drug was still entrapped in the AEA-coated SDN–MMT 
nanohybrid, which was not released under a simulated in 
vitro condition. However, many different types of cations 
possibly present in the living body may continuously replace 
the entrapped drug molecules to facilitate drug diffusion 
out.46–48 Therefore, the remaining 10% of SDN would be 
released in a sustained manner after the nanohybrid passed 
the gastric cavity. In the intestine, the polymeric barrier of 
AEA would not be present due to its complete dissolution 
in a gastric fluid.
Viagra® released almost all drug in 10 minutes, which 
would allow high systemic absorption at the early stage, 
resulting in a faster Tmax (1 hour), while the absorption of 
SDN was delayed in the AEA-coated SDN–MMT because 
the drug entrapped in the interlayer of MMT was released 
slowly during its passage through the gastrointestinal tract 
(Tmax = 2.33 hours). For the specific drug, SDN, a faster onset 
of pharmacodynamic response (ie, a faster Tmax) would be 
still desirable. For this reason, our nanohybrid systems need 
to be further improved to achieve faster drug release at an 
early stage in addition to taste masking of the drug. In this 
sense, we envision using more AEA or employing other cat-
ionic macromolecules for coating our nanohybrid systems to 
facilitate deintercalation of the drug and enhance drug release 
in the gastric cavity.32
Stability of SDN
The drug molecules in nanohybrids could be more sensitive 
to degradation due to their distribution at a molecular level, 
100
10
5
0510 15
Time (hours)
P
l
a
s
m
a
 
c
o
n
c
.
 
o
f
 
s
l
i
d
e
n
a
f
i
l
 
(
µ
g
/
m
L
)
20 25
0.1
Figure 6 Mean plasma concentration–time curves of sildenafil after oral administration of Viagra® (●) and polyvinylacetal diethylaminoacetate (AEA)-coated hybrid (○) to 
the beagle dogs.
Table  2  Pharmacokinetic  parameters  of  SDN  after  oral 
administration  of Viagra®  and AEA-coated  nanohybrids  to  the 
beagle dogs
Parameters Viagra®a AEA-coated nanohybrida
AUC0-∞ (µg ⋅ hour/mL) 69.2 ± 3.19 78.8 ± 2.32*
Cmax (µg/mL) 10.5 ± 0.641 12.4 ± 0.673*
Tmax (hours) 1.00 2.33 ± 0.577
t1/2 (hours) 5.00 ± 0.074 4.13 ± 0.785
Vd/F (L) 31.3 ± 1.19 22.7 ± 4.49*
Cl/F (L/hour) 4.34 ± 0.205 3.81 ± 0.112*
Notes: aValues are mean ± SD; n = 3; *P , 0.05 compared with Viagra®.
Abbreviations:  AEA,  polyvinylacetal  diethylaminoacetate;  AUC0-∞,  area  under 
the plasma concentration-time curve from 0 hours to infinity; Cl/F, total clearance; 
Cmax, maximum plasma concentration; SD, standard deviation; SDN, sildenafil; Tmax, time 
required to reach Cmax; t1/2, elimination half-life; Vd/F, apparent volume of distribution.
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giving a higher chance of interaction with the surrounding 
environment. Therefore, we assessed the shelf-life of 
SDN–MMT and AEA-coated SDN–MMT nanohybrids under 
an accelerated stability test condition (temperature, 40°C; 
humidity, 75%).49 As shown in Table 3, the changes in 
nondegraded SDN content during 6 months were minimal 
(,±5%) for all samples, indicating that the SDN molecules 
could be well protected in the interlayer space of MMT due 
to their strong ionic interaction.
Conclusion
In this study, we suggest nanohybrids as a potential oral 
disintegrating formulation for delivery of SDN, a drug for 
treatment of erectile dysfunction. For this purpose, the drug 
was intercalated into MMT by cation exchange reaction to 
produce an SDN–MMT nanohybrid for taste masking of SDN. 
In order to improve the release rate in the simulated gastric 
fluid, the SDN–MMT nanohybrid was further coated with 
AEA, a cationic polymer, which exhibited suppressed release 
under a simulated buccal condition. For in vitro drug release in 
a simulated gastric fluid, AEA-coated SDN–MMT exhibited 
relatively fast drug release, ie, 80% during the first 10 minutes 
and 10% during the remaining 110 minutes. However, the 
total percentage of drug release was about 10% lower than 
Viagra®. The in vivo pharmacokinetic study revealed that the 
AUC0-∞ and Cmax values of SDN were significantly increased 
with AEA-coated SDN–MMT nanohybrid compared with 
Viagra®. Therefore, we conclude that the nanohybrid system 
suggested in this work has potential for taste masking of SDN 
as well as possibly increased drug exposure.
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Table S4 Release profiles of sildenafil from (A) SDN–MMT, (B) AEA-coated SDN–MMT, (C) Viagra®, and (D) sildenafil citrate. The 
release experiments were performed at pH = 1.2
Samples % drug releasea
10  
minutes
20  
minutes
40  
minutes
60  
minutes
90  
minutes
120  
minutes
(A) SDN–MMT 0.00  
(±0.00)
0.00  
(±0.00)
0.51  
(±0.44)
1.33  
(±0.06)
1.92  
(±0.34)
2.58  
(±0.26)
(B) AEA-coated SDN–MMT 78.40  
(±1.10)
84.22  
(±0.43)
87.93  
(±0.51)
89.36  
(±0.71)
90.52  
(±0.59)
91.43  
(±0.69)
(C) Viagra® 93.56  
(±7.60)
94.03  
(±7.21)
95.39  
(±5.87)
96.43  
(±4.73)
98.00  
(±3.42)
99.12  
(±2.55)
(D) Sildenafil citrate 97.49  
(±1.06)
98.11  
(±0.75)
98.33  
(±0.30)
99.10  
(±0.45)
99.30  
(±0.30)
100.11  
(±0.22)
Notes: aValues are mean ± SD; n = 3.
Abbreviations: AEA, polyvinylacetal diethylaminoacetate; SD, standard deviation; SDN–MMT, sildenafil–montmorillonite.
Supplementary information
Table  S1 Accuracy  and  precision  of  SDN  analyses  in  plasma 
samples
SDN  
(n = 15)
Concentration (ng/mL) RSD  
(%)
Accuracy   
(%) Added Found (mean ± SD)
Intraday
5.00     4.73 ± 0.19 3.8 94.6
50.00   45.87 ± 2.32 4.6 91.7
150.00 144.32 ± 6.01 4.0 96.2
Interday
5.00     4.55 ± 0.22 4.4 91.0
50.00   46.31 ± 2.20 4.4 92.6
150.00 140.40 ± 6.82 4.5 93.6
Abbreviations: SD,  standard deviation; SDN, sildenafil; RSD,  relative  standard 
deviation.
Table S2 Recovery of SDN spiked into plasma samples
SDN  
(n = 3)
Concentration (ng/mL) Recovery   
(%) Expected Found (mean ± SD)
2.00   1.83 ± 0.13 91.5
20.00 18.28 ± 1.28 91.4
100.00 93.62 ± 6.08 93.6
Abbreviations: SD, standard deviation; SDN, sildenafil.
Table S3 In vitro drug dissolution profiles under a simulated buccal and gastric fluid condition
Conditions % drug releasea
Viagra® Sildenafil citrate SDN–MMT AEA-coated SDN–MMT
pH 7.0  
(buccal cavity,  
2 minutes)
48.78 ± 5.49   73.66 ± 4.61 0.00 ± 0.00   4.70 ± 0.53
pH 1.2  
(gastric fluid,  
120 minutes)
99.12 ± 2.55 100.11 ± 0.22 2.58 ± 0.26 91.43 ± 0.69
Notes: aValues are mean ± SD; n = 3.
Abbreviations: AEA, polyvinylacetal diethylaminoacetate; SD, standard deviation; SDN–MMT, sildenafil–montmorillonite.
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Figure S1 Fourier transform infrared spectra of (A) sildenafil citrate, (B) montmorillonite (MMT), (C) sildenafil–montmorillonite (SDN–MMT), and (D) polyvinylacetal 
diethylaminoacetate (AEA)-coated SDN–MMT.
Notes: The circles (•) and the dashed vertical lines show the characteristic peaks seen with intact SDN and MMT.
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Figure S2 The particle size distribution of (A) sildenafil–montmorillonite (SDN–MMT) and (B) polyvinylacetal diethylaminoacetate (AEA)-coated SDN–MMT.
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Figure S3 Typical electrospray ionization mass spectrometry/mass spectrometry spectra of authentic sildenafil.
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Figure S4 Representative chromatograms of (A) sildenafil detected in a plasma sample collected for 2 hours after sildenafil administration, and (B) blank plasma sample 
collected just before sildenafil administration.
Abbreviations: ES, electrospray; MRM, multiple reaction monitoring; TIC, total ion count.
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Nanohybrids for taste masking of sildenafil